– Mubadala Investment Company has acquired 100% ownership of UCB Pharma’s mature business in China, in partnership with CBC Group, a healthcare-focused asset manager.

– The acquisition strengthens Mubadala’s presence in the Asian healthcare market, covering UCB’s neurology and allergy portfolios, including drugs like Keppra, Vimpat, and Zyrtec.

– The transaction, expected to close in Q4 2024, includes UCB’s Zhuhai manufacturing facility and is subject to regulatory approvals.

The UAE’s Mubadala Investment Company has secured 100% ownership of UCB Pharma’s established business operations in China, in collaboration with healthcare-focused asset manager CBC Group.

UCB, a Belgium-based global biopharmaceutical firm, is well-established in China’s expanding immunology and neurology sectors.

Details regarding the size of Mubadala’s stake and the financial terms of the transaction have not been disclosed. The deal is expected to close by the fourth quarter of 2024.

This acquisition aligns with Mubadala’s strategic focus on strengthening its foothold in Asia, particularly within the rapidly expanding healthcare market, the company stated on X. The purchase includes UCB’s neurology portfolio, featuring prominent drugs such as Keppra, Vimpat, and Neupro, which are essential for treating epilepsy and other neurological disorders—areas of growing demand in China.

Additionally, the deal encompasses UCB’s allergy treatment portfolio, including the popular antihistamines Zyrtec and Xyzal.

In 2023, these products generated €131 million ($146 million) in net sales within China. The transaction is subject to regulatory approvals, including antitrust clearances.

Mubadala and CBC Group also acquired UCB’s Zhuhai manufacturing facility, a critical site for producing and distributing these medications throughout mainland China.